Celsius vs C4 Therapeutics

Celsius Holdings Inc. and C4 Therapeutics Inc. are two distinct companies operating in the health and wellness industry. Celsius focuses on producing fitness drinks and nutritional supplements, while C4 Therapeutics is dedicated to developing targeted protein degradation therapies for various diseases. Both stocks have shown promising growth potential in their respective fields, attracting investors looking to capitalize on the expanding health and wellness market. This comparison highlights the unique opportunities and challenges associated with investing in Celsius versus C4 Therapeutics stocks.

Celsius or C4 Therapeutics?

When comparing Celsius and C4 Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Celsius and C4 Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Celsius has a dividend yield of -%, while C4 Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Celsius reports a 5-year dividend growth of 0.00% year and a payout ratio of 9.80%. On the other hand, C4 Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Celsius P/E ratio at 28.39 and C4 Therapeutics's P/E ratio at -4.02. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Celsius P/B ratio is 6.42 while C4 Therapeutics's P/B ratio is 1.75.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Celsius has seen a 5-year revenue growth of 15.30%, while C4 Therapeutics's is -0.68%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Celsius's ROE at 24.78% and C4 Therapeutics's ROE at -44.60%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $33.55 for Celsius and $5.84 for C4 Therapeutics. Over the past year, Celsius's prices ranged from $28.20 to $99.62, with a yearly change of 253.26%. C4 Therapeutics's prices fluctuated between $1.06 and $11.88, with a yearly change of 1020.75%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.